TCM's Output To Hit RMB 400 Billion Over Next Decade
This article was originally published in PharmAsia News
Executive SummaryAt the recent 2009 International Conference for Bioeconomy, the Ministry of Science and Technology's China National Center for Biotechnology Development disclosed that the country will further push for TCM modernization and establish a healthcare system of integrating Western and Chinese medicine. TCM industry value is expected to hit RMB 400 billion ($58.5 billion) over the next 10 years. In addition, China will make TCM healthcare a key pillar for the population, such that 85 percent of rural residents can access such medical services. TCM industry value has been increasing at an average annual rate of 20 percent in recent years to reach almost a hundred billion renminbi, higher than the pharmaceutical industry's average. (Click here for more - Chinese Language)
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.